Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Update

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 105,700 shares, a decline of 40.5% from the January 15th total of 177,500 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 134,400 shares, the days-to-cover ratio is presently 0.8 days.

Analyst Ratings Changes

Separately, Craig Hallum set a $1.50 target price on shares of Xtant Medical and gave the company a “buy” rating in a research report on Friday, October 18th.

Xtant Medical Price Performance

Shares of NYSEAMERICAN:XTNT traded up $0.02 on Thursday, reaching $0.58. The company’s stock had a trading volume of 12,412 shares, compared to its average volume of 53,676. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12. Xtant Medical has a 52-week low of $0.33 and a 52-week high of $1.30. The stock has a market capitalization of $80.21 million, a price-to-earnings ratio of -4.44 and a beta of 0.35.

Xtant Medical (NYSEAMERICAN:XTNT) last released its earnings results on Tuesday, November 12th. The medical device company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%. The business had revenue of $27.94 million during the quarter.

Hedge Funds Weigh In On Xtant Medical

A hedge fund recently raised its stake in Xtant Medical stock. Geode Capital Management LLC raised its stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 515,006 shares of the medical device company’s stock after buying an additional 212,394 shares during the period. Geode Capital Management LLC owned approximately 0.37% of Xtant Medical worth $348,000 at the end of the most recent reporting period. 69.33% of the stock is currently owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.